Personalized Radiation Therapy for GBM
Not Applicable
Active, not recruiting
- Conditions
- Glioblastoma
- Registration Number
- NCT03477513
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Brief Summary
The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival. Toxicity, patterns of recurrence, and overall median survival will be measured as secondary endpoints. Adverse events will be monitored.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Patients with biopsy-proven WHO Grade IV glioblastoma, after gross-total or near-total resection, who are undergoing definitive chemoradiation as part of their treatment regimen
- Age 18 or older
- Ability to give signed informed consent
- Karnofsky Performance Status (KPS) at least 70
Exclusion Criteria
- Placement of Gliadel wafers
- Participation in another investigational trial
- Active treatment of another malignancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Adverse Events 2 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Abramson Cancer Center of the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Abramson Cancer Center of the University of Pennsylvania🇺🇸Philadelphia, Pennsylvania, United States